Repligen(RGEN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $198 million, representing an 18% year-over-year increase and 14% organic growth, exceeding guidance [5][23] - Full year revenue reached $738 million, with a reported growth of 16% and organic growth of 14% [5][23] - Adjusted operating margin for the fourth quarter was 15%, reflecting a 10 basis point increase year-over-year, and 240 basis points expansion excluding M&A and foreign currency impacts [26][27] Business Line Data and Key Metrics Changes - Proteins and process analytics both grew over 30% in the fourth quarter, while chromatography grew more than 25% [5][6] - For the full year, protein revenue grew 31%, and analytics grew 37% on a reported basis [6][21] - Filtration revenue grew high single digits for both the quarter and the year, driven by consumables [6][18] Market Data and Key Metrics Changes - North America represented approximately 47% of total revenue, growing mid-teens, while EMEA grew more than 20% [24] - Asia Pacific grew high teens, with China showing signs of recovery after a decline in 2025 [24] - Biopharma revenue grew over 20% year-over-year, with strong growth across all geographies [10][24] Company Strategy and Development Direction - The company aims to outpace bioprocessing industry growth, drive operating leverage, and continue innovation through new product launches [21][22] - Focus on integrating recent acquisitions and pursuing additional M&A opportunities remains a priority [16][22] - The company is committed to margin expansion while balancing investments for future growth [9][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about a strengthening macro backdrop, including improved biotech funding and M&A activity [9] - The guidance for 2026 is set at $810 million-$840 million, reflecting a 9%-13% organic revenue growth expectation [8][31] - Management acknowledged potential headwinds from FDA policy and biopharma's strategic responses to market changes [9][53] Other Important Information - The company expanded adjusted operating margin by 90 basis points to 13.8% in 2025, with significant investments in leadership and technology [13][27] - Cash and marketable securities at the end of the fourth quarter totaled $768 million, up $90 million sequentially [28][36] Q&A Session Summary Question: Customer confidence regarding the policy environment and tariff updates - Management noted that tariffs are a significant open question but do not create substantial noise as they represent less than 1% of total sales [40][41] - There is a strong funnel of opportunities with high probability, indicating a positive outlook for converting these into orders [42] Question: Commitment to operating margin expansion versus M&A - Management emphasized that margin expansion remains a top priority, alongside above-market growth, while acknowledging the strategic merits of potential acquisitions [46][47] Question: Pacing of revenue growth and market normalization - Management indicated that while they expect a normal first half versus second half revenue split, they are optimistic about starting Q1 strong with only a slight sequential decline [50][55] Question: Clarification on organic growth expectations - Management confirmed that the guidance for 2026 is appropriate, with a strong funnel of opportunities across the product portfolio [67]